Please ensure Javascript is enabled for purposes of website accessibility

Jazz Pharma Files for FDA Approval of a New Narcolepsy Drug

By Todd Campbell - Updated Jan 22, 2020 at 8:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's submitted an application for approval of JZP-258, a treatment for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.

Jazz Pharmaceuticals plc (JAZZ 3.51%) has submitted an application for Food and Drug Administration (FDA) approval of JZP-258, a new drug for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy age 7 and up. To speed along an FDA review of JZP-258, the company is redeeming a priority review voucher that shortens the FDA's decision timeline from 10 months to six months.

A woman sleeping while standing.

Image source: Getty Images.

The loss of muscle tone while conscious, or cataplexy, and EDS are two of the five primary symptoms of narcolepsy. EDS affects every patient, while roughly 70% of patients experience cataplexy. If approved, JZP-258 could become an important treatment option, particularly in patients on a sodium-restricted diet due to cardiovascular disease or hypertension.

Cardiometabolic comorbidities, including obesity and hypertension, are common in narcolepsy, so many people aren't prescribed Jazz Therapeutics' existing blockbuster narcolepsy drug, Xyrem, which is formulated with sodium. JZP-258 contains the same active ingredient as Xyrem; however, it uses non-sodium cations, including calcium, magnesium, and potassium, in its formulation to reduce sodium levels by 92%.

Jazz Pharmaceuticals estimates that fewer than 50% of U.S. narcolepsy patients, or 75,000 people, are diagnosed and currently being treated. At the JP Morgan Healthcare Conference earlier this month, Jazz Pharmaceuticals indicated it expects an FDA decision during the third quarter. If JZP-258 is approved, then the company's plan is to begin marketing it as early as the fourth quarter of 2020. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$152.31 (3.51%) $5.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.